FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry comments lead to subtle but notable changes; agency also makes a few deletions, additions of its own including deemphasizing cost-control projects, highlighting antibiotic development and changing the status of its facility improvements.
You may also be interested in...
FDA Budget Issues Creep Into Strategic Priorities
“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.